| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IDS |
| Uniprot No | P22304 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-550aa |
| 氨基酸序列 | SETQANSTTDALNVLLIIVDDLRPSLGCYGDKLVRSPNIDQLASHSLLFQ NAFAQQAVCAPSRVSFLTGRRPDTTRLYDFNSYWRVHAGNFSTIPQYFKE NGYVTMSVGKVFHPGISSNHTDDSPYSWSFPPYHPSSEKYENTKTCRGPD GELHANLLCPVDVLDVPEGTLPDKQSTEQAIQLLEKMKTSASPFFLAVGY HKPHIPFRYPKEFQKLYPLENITLAPDPEVPDGLPPVAYNPWMDIRQRED VQALNISVPYGPIPVDFQRKIRQSYFASVSYLDTQVGRLLSALDDLQLAN STIIAFTSDHGWALGEHGEWAKYSNFDVATHVPLIFYVPGRTASLPEAGE KLFPYLDPFDSASQLMEPGRQSMDLVELVSLFPTLAGLAGLQVPPRCPVP SFHVELCREGKNLLKHFRFRDLEEDPYLPGNPRELIAYSQYPRPSDIPQW NSDKPSLKDIKIMGYSIRTIDYRYTVWVGFNPDEFLANFSDIHAGELYFV DSDPLQDHNMYNDSQGGDLFQLLMPLEHHHHHH |
| 预测分子量 | 60 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与IDS重组蛋白相关的文献示例(内容基于领域内典型研究方向，非真实文献，供参考)：
1. **《Recombinant human idursulfase for mucopolysaccharidosis II: production and preclinical evaluation》**
- **作者**: Muenzer J. et al.
- **摘要**: 研究描述了重组人IDS酶(idursulfase)的哺乳动物细胞表达系统开发，通过体外和动物模型验证其酶活性及对硫酸乙酰肝素/硫酸皮肤素降解的有效性，支持其作为MPS II的酶替代疗法。
2. **《Enhanced stability and efficacy of PEGylated recombinant iduronate-2-sulfatase》**
- **作者**: Giugliani R. et al.
- **摘要**: 通过聚乙二醇(PEG)修饰重组IDS蛋白，改善其血浆半衰期和稳定性，并在小鼠模型中证明修饰后酶的组织渗透性和代谢底物清除效率显著提升。
3. **《Fusion protein strategies for improved targeting of iduronate-2-sulfatase to lysosomes》**
- **作者**: Kubo T. et al.
- **摘要**: 提出将IDS与靶向溶酶体的多肽融合，通过细胞实验证实融合蛋白更高效地被细胞摄取并递送至溶酶体，为优化重组IDS的疗效提供新策略。
4. **《Long-term outcomes of idursulfase beta in patients with Hunter syndrome: a phase III trial》**
- **作者**: Okuyama T. et al.
- **摘要**: 多中心III期临床试验评估重组IDS酶(idursulfase beta)的长期安全性和有效性，结果显示患者尿糖胺聚糖水平持续降低，且肝脾肿大和关节活动度等症状显著改善。
(注：以上文献名为虚构，作者和摘要内容为领域典型研究方向示例，实际引用需以真实发表文献为准。)
**Background of Recombinant IDS Protein**
Iduronate 2-sulfatase (IDS) is a lysosomal enzyme encoded by the *IDS* gene, responsible for catalyzing the hydrolysis of sulfate groups from glycosaminoglycans (GAGs), such as heparan sulfate and dermatan sulfate. Deficiency in IDS activity leads to mucopolysaccharidosis type II (MPS II or Hunter syndrome), a rare X-linked lysosomal storage disorder characterized by progressive GAG accumulation, resulting in multisystemic damage, neurological decline, and reduced lifespan.
Recombinant IDS protein (e.g., idursulfase) is produced via genetic engineering in mammalian cell systems (e.g., Chinese hamster ovary or human cell lines) to restore enzymatic activity in patients. Approved for enzyme replacement therapy (ERT), it mitigates somatic symptoms (e.g., hepatosplenomegaly, respiratory issues) by intravenous infusion. However, its efficacy is limited by poor blood-brain barrier (BBB) penetration, leaving neurological manifestations untreated.
Research focuses on enhancing recombinant IDS delivery, including engineered variants with improved stability, fusion proteins enabling receptor-mediated BBB transit (e.g., antibody-IDS conjugates), and gene therapy approaches. Clinical trials highlight measurable reductions in urinary GAG levels and functional improvements, though long-term outcomes vary. Challenges remain in addressing immune responses, optimizing dosing, and achieving cost-effective production.
Overall, recombinant IDS represents a cornerstone in MPS II management, with ongoing innovations aiming to broaden therapeutic impact, particularly for CNS involvement, while underscoring the need for personalized treatment strategies.
×
